-

NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference

BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, today announced management’s participation in two upcoming investor conferences.

BioPharm America
September 28 – 29, 2022
Boston (In-person event)
JS Cleiftie, MS, MBA, Chief Business Officer and Head of Finance
Available for one-on-one meetings

Chardan’s 6th Annual Genetic Medicines Conference
October 3 – 4, 2022
NYC (In-person event)
Dominique Verhelle, PhD, MBA, Co-Founder, Chief Executive Officer and Chief Scientific Officer
Corporate Presentation: Mon., Oct. 3, 10:30 – 10:55 am
Long Non-Coding RNA Panel: Mon., Oct. 3, 3:00 – 3:45 pm

About NextRNA Therapeutics

NextRNA is a biotechnology company unlocking the potential of non-coding RNAs to develop transformative medicines for multiple diseases. The company is leveraging its proprietary technology platform to identify non-coding RNAs and their interacting proteins responsible for disease, and to develop selective small molecules to disrupt these interactions.

For more information, please visit www.nextrnatx.com.

Contacts

Media:
Liz Melone
PR@NextRNA.com

Industry:

NextRNA Therapeutics

Details
Headquarters: Boston, Massachusetts
Website: nextrnatx.com
CEO: Dominique Verhelle
Employees: 28
Organization: PRI
Release Versions
English

Contacts

Media:
Liz Melone
PR@NextRNA.com

More News From NextRNA Therapeutics

NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors

BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced the appointment of Charles (Chuck) Kunsch, Ph.D., to its Board of Directors. Currently a Venture Partner at Dreavent Capital, Dr. Kunsch previously served as Managing Director at AbbVie Ventures for more than a decade. “We’re excited to welcome Dr. Chuck Kunsch to NextRNA’s Board of Directors. His deep, div...

NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer

BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced the appointment of Jesse Smith, Ph.D., as Chief Scientific Officer (CSO). Dr. Smith brings to NextRNA over 20 years of drug discovery and development experience with a deep focus on advancing first-in-class targeted small molecule therapies. lncRNAs represent a vast class of therapeutic targets that recruit...

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors. Dr. Friedman is currently Chief Scientific Officer of ORIC Pharmaceuticals, Inc. and formerly served as head of translational oncology for Genentech Research and Early Development (...
Back to Newsroom